Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

About the QuANTUM-Wild Study: QuANTUM-Wild is a clinical trial for people who are newly diagnosed with acute myeloid leukaemia (AML) that is FLT3-ITD–negative. The purpose of the clinical trial is to evaluate an oral study drug called quizartinib—to see if it may improve this type of AML and is safe. This study drug is currently not approved for this condition, which is why it’s being evaluated. Everyone in the clinical trial will also receive the standard chemotherapy for their type of AML. This clinical trial will not delay the start of chemotherapy. Your study doctor may recommend that you receive a stem cell transplant. If so, your study doctor will be able to provide you with more information about this procedure. Although it is not part of this clinical trial, you may be able to continue participating in the clinical trial after you receive a stem cell transplant.

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

A/Prof Shaun Fleming

Key inclusion data

How do I qualify? You may be eligible to participate if: You are between 18 to 70 years of age; You have AML that is FLT3- ITD—negative; You are newly diagnosed with AML and have not yet received treatment for AML.